Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Yoshiaki Murakami

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6208-3081; OpenAlex author ID A5016890878. Sources: OpenAlex.

Their work

Papers
52 (first author 16, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
126
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: none · 2014: 1 paper · 2015: 5 papers · 2016: 6 papers · 2017: 3 papers · 2018: 4 papers · 2019: 3 papers · 2020: 6 papers · 2021: 7 papers · 2022: 5 papers · 2023: 3 papers · 2024: 2 papers · 2025: 2 papers · 2026: 3 papers

Papers 50 of 52

  1. Independent Prognostic Value of Natural Tooth Count Versus Posterior Teeth Occlusion in Resected Pancreatic Cancer. Co-author DOI 10.1002/jhbp.70113↗
  2. Aso Visual Abstract: Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18555-4↗
  3. Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20710-4↗
  4. Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ags3.12898↗
  5. Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-17988-1↗
  6. Long-term outcomes of neoadjuvant gemcitabine, nab-paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer with arterial contact: Results from a ph… Co-author DOI 10.1002/jhbp.1412↗
  7. Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15221-z↗
  8. Surgical resection for liver recurrence after curative resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-023-03009-w↗
  9. Prognostic factor in patient with recurrent pancreatic adenocarcinoma. Co-author DOI 10.1007/s00423-023-03073-2↗
  10. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery… Co-author DOI 10.1016/j.pan.2023.07.005↗
  11. Prognosis following an extended duration of adjuvant gemcitabine plus S-1 chemotherapy in patients with pancreatic ductal adenocarcinoma: Analysis using invers… Co-author DOI 10.1002/jhbp.1151↗
  12. Neoadjuvant therapy contributes to nodal downstaging of pancreatic cancer. Co-author DOI 10.1007/s00423-021-02339-x↗
  13. Long-term survival after distal pancreatectomy with celiac axis resection and hepatic artery reconstruction in the setting of locally advanced unresectable pan… Co-author DOI 10.1007/s12328-022-01621-9↗
  14. Impact of disintegrin and metalloproteinase domain-containing protein 12 on pancreatic ductal adenocarcinoma treated with surgical resection and perioperative … Co-author DOI 10.1016/j.pan.2022.03.018↗
  15. Preoperative risk factors for positivity of peritoneal lavage cytology in patients with pancreatic ductal adenocarcinoma in the era of neoadjuvant therapy. Co-author DOI 10.1016/j.pan.2022.04.004↗
  16. Prognostic significance of dissecting the nerve plexus around the common hepatic artery in pancreatic cancer. Co-author DOI 10.1007/s00423-020-02025-4↗
  17. Prognostic Value of Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma Stratified by the Resectability Status. Co-author DOI 10.1007/s11605-021-04978-3↗
  18. A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial… Co-author DOI 10.1016/j.ejca.2021.10.012↗
  19. Preoperative risk factors for para-aortic lymph node positivity in pancreatic cancer. Co-author DOI 10.1016/j.pan.2021.01.022↗
  20. Left-sided Portal Hypertension After Pancreaticoduodenectomy With Resection of the Portal Vein/Superior Mesenteric Vein Confluence in Patients With Pancreatic … Co-author DOI 10.1097/sla.0000000000003487↗
  21. Identification of Preoperative Risk Factors for Poor Survival in Patients with Resectable Pancreatic Cancer Treated with Upfront Surgery. Co-author DOI 10.1159/000520064↗
  22. Clinical Implications of Pre- and Postoperative Circulating Tumor DNA in Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-09278-9↗
  23. Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. Co-author DOI 10.1002/bjs.11792↗
  24. Reappraisal of the validity of surgery for patients with pancreatic cancer aged 80 years or older stratified by resectability status. Last author DOI 10.1002/jhbp.687↗
  25. Immunohistological evaluation of mismatch repair deficiency in pancreatic ductal adenocarcinoma treated with surgical resection. First author DOI 10.1002/jhbp.737↗
  26. Neoadjuvant therapy for pancreatic cancer: an intention-to-treat analysis. First author DOI 10.1007/s00423-020-01914-y↗
  27. Clinical characteristics of initial recurrence in lung after surgical resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.08.019↗
  28. Optimal Treatment for Octogenarians With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Retrospective Study. Co-author DOI 10.1097/mpa.0000000000001579↗
  29. Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively … First author DOI 10.1007/s00268-018-4814-4↗
  30. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicente… Co-author DOI 10.1186/s12885-019-5460-4↗
  31. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializi… Co-author DOI 10.1245/s10434-018-07131-8↗
  32. Prognostic impact of postoperative complication after pancreatoduodenectomy for pancreatic adenocarcinoma stratified by the resectability status. First author DOI 10.1002/jso.25066↗
  33. Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic ductal adenocarcinoma? -Multicenter surgica… Last author DOI 10.1016/j.pan.2017.11.005↗
  34. The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuva… Co-author DOI 10.1016/j.pan.2017.12.014↗
  35. MAPLE-PD trial (Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer during Pancreaticoduodenectomy): study protocol for a multicenter randomize… Co-author DOI 10.1186/s13063-018-3002-z↗
  36. Retrospective Study of the Correlation Between Pathological Tumor Size and Survival After Curative Resection of T3 Pancreatic Adenocarcinoma: Proposal for Recl… Co-author DOI 10.1007/s00268-017-4077-5↗
  37. A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma. First author DOI 10.1007/s00280-017-3274-0↗
  38. Effect of Neoadjuvant Nab-Paclitaxel plus Gemcitabine Therapy on Overall Survival in Patients with Borderline Resectable Pancreatic Cancer: A Prospective Multi… Co-author DOI 10.1159/000478660↗
  39. Prognosis after surgical treatment for pancreatic cancer in patients aged 80 years or older: a multicenter study. First author DOI 10.1002/jhbp.320↗
  40. Grade B pancreatic fistulas do not affect survival after pancreatectomy for pancreatic cancer: A multicenter observational study. First author DOI 10.1016/j.surg.2016.02.032↗
  41. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer. First author DOI 10.1038/bjc.2016.175↗
  42. Reappraisal of Total Pancreatectomy in 45 Patients With Pancreatic Ductal Adenocarcinoma in the Modern Era Using Matched-Pairs Analysis: Multicenter Study Grou… First author DOI 10.1097/mpa.0000000000000579↗
  43. Preoperative Biliary Drainage in Cases of Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Chemotherapy and Surgery. Co-author DOI 10.1155/2016/7968201↗
  44. Prognostic Impact of Para-Aortic Lymph Node Micrometastasis in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-016-5120-8↗
  45. Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients. First author DOI 10.1007/s00535-014-1005-4↗
  46. Reappraisal of peritoneal washing cytology in 984 patients with pancreatic ductal adenocarcinoma who underwent margin-negative resection. First author DOI 10.1007/s11605-014-2637-7↗
  47. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center r… First author DOI 10.1016/j.pan.2015.09.008↗
  48. An Increased Number of Perineural Invasions Is Independently Associated With Poor Survival of Patients With Resectable Pancreatic Ductal Adenocarcinoma. First author DOI 10.1097/mpa.0000000000000413↗
  49. Impact of Preoperative Biliary Drainage on Long-Term Survival in Resected Pancreatic Ductal Adenocarcinoma: A Multicenter Observational Study. First author DOI 10.1245/s10434-015-4618-9↗
  50. Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: project study by the Japanese Soc… Co-author DOI 10.1002/jhbp.15↗

Closest collaborators

The 25 strongest of 126 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenichiro Uemura · 42 shared papers, 2011–2026 · strength 4.70
  2. Kenjiro Okada · 23 shared papers, 2018–2026 · strength 3.67
  3. Shin’ya Takahashi · 24 shared papers, 2016–2025 · strength 3.32
  4. Tatsuaki Sumiyoshi · 18 shared papers, 2020–2026 · strength 3.09
  5. Naru Kondo · 23 shared papers, 2011–2024 · strength 2.69
  6. Hiroyuki Otsuka · 15 shared papers, 2020–2023 · strength 2.11
  7. Sohei Satoi · 21 shared papers, 2014–2026 · strength 1.68
  8. Masayuki Sho · 19 shared papers, 2014–2026 · strength 1.51
  9. Hiroki Yamaue · 19 shared papers, 2014–2026 · strength 1.47
  10. Ryuta Shintakuya · 7 shared papers, 2018–2026 · strength 1.46
  11. Yasutaka Ishii · 8 shared papers, 2016–2026 · strength 1.36
  12. Michiaki Unno · 15 shared papers, 2014–2026 · strength 1.13
  13. Goro Honda · 14 shared papers, 2014–2026 · strength 1.05
  14. Takumi Harada · 4 shared papers, 2024–2026 · strength 0.91
  15. Ippei Matsumoto · 15 shared papers, 2014–2023 · strength 0.86
  16. Kenta Baba · 4 shared papers, 2023–2025 · strength 0.81
  17. Fuyuhiko Motoi · 13 shared papers, 2014–2020 · strength 0.70
  18. Suguru Yamada · 5 shared papers, 2017–2026 · strength 0.66
  19. Shuji Isaji · 4 shared papers, 2019–2026 · strength 0.65
  20. Satoshi Hirano · 4 shared papers, 2020–2026 · strength 0.62
  21. Taijiro Sueda · 8 shared papers, 2011–2021 · strength 0.58
  22. Masanao Kurata · 11 shared papers, 2015–2019 · strength 0.58
  23. Tsutomu Fujii · 6 shared papers, 2018–2023 · strength 0.57
  24. Itaru Endo · 3 shared papers, 2019–2026 · strength 0.52
  25. Takumi Fukumoto · 10 shared papers, 2015–2019 · strength 0.51

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.